Literature DB >> 29707339

Effect of low molecular weight heparin on venous thromboembolism disease in thoracotomy patients with cancer.

Jun Dong1, Jia Wang2, Yuan Feng2, Li-Ping Qi3, Hua Fang1, Guo-Dong Wang1, Zhou-Qiao Wu4, Hong-Zhi Wang1, Yue Yang2, Qing Li1.   

Abstract

BACKGROUND: Much attention has been given to venous thromboembolism (VTE) disease, and many guidelines for prophylaxis have been published. However, there are few published data on patients who underwent thoracotomy. This study is to compare the effect of low molecular weight heparin (LMWH) combined mechanical approaches with mechanical approaches alone in prevention of VTE in the post thoracotomy cancer patients.
METHODS: This study used a prospective, randomized-controlled design. Patients with cancer who were scheduled for thoracotomy were divided into two groups: group A and group B. In group A, patients were given intermittent pneumatic compression (IPC) and elastic stockings (ES) postoperatively. Additionally, at 24 hours post-operation, patients were subcutaneously injected with LMWH calcium (nadroparin calcium; GlaxoSmithKline, China) for 7 days. In group B, patients were only given postoperative IPC and ES. The primary end points were incidence of pulmonary embolism (PE), deep vein thrombosis (DVT), and the PE severity index (PESI) of PE patients. The secondary end points were hemoglobin (HGB), platelet (PLT), D-dimer, the PO2/FiO2 ratio (P/F) at postoperative day (POD) 7, the chest drainage time (CDT) and the length of stay (LOS) in hospital after operation.
RESULTS: A total of 90 patients were included in the final data analysis (40 patients in group A and 50 patients in group B). At POD7, the incidence of PE, DVT and PESI was 17.50%, 5.00% and 102.14±9.87, respectively, in group A. And 8.00%, 8.00% and 97.00±4.24, respectively, in group B. There were no significant differences between two groups (all P values were >0.05). There were no significant differences of HGB, PLT, D-dimer and P/F between two groups at the 7th day post operation (all P value >0.05).
CONCLUSIONS: LMWH combined mechanical prophylaxis did not significant reduced the rate of VTE in thoracotomy cancer patients.

Entities:  

Keywords:  Venous thromboembolism disease (VTE disease); low molecular weight heparin (LMWH); prophylaxis, cancer; thoracotomy

Year:  2018        PMID: 29707339      PMCID: PMC5906297          DOI: 10.21037/jtd.2018.03.13

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  19 in total

Review 1.  Pulmonary embolism prophylaxis: evidence for utility in thoracic surgery.

Authors:  Dean M Donahue
Journal:  Thorac Surg Clin       Date:  2005-05       Impact factor: 1.750

2.  High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism.

Authors:  P Girard; D Musset; F Parent; S Maitre; C Phlippoteau; G Simonneau
Journal:  Chest       Date:  1999-10       Impact factor: 9.410

3.  Prevalence of venous thromboembolism in elective thoracic surgery.

Authors:  María Teresa Gómez-Hernández; María Rodríguez-Pérez; Nuria Novoa-Valentín; Marcelo Jiménez-López; José Luis Aranda-Alcaide; Gonzalo Varela-Simó
Journal:  Arch Bronconeumol       Date:  2013-03-28       Impact factor: 4.872

Review 4.  Mechanical compression versus subcutaneous heparin therapy in postoperative and posttrauma patients: a systematic review and meta-analysis.

Authors:  Robert W Eppsteiner; Jennifer J Shin; Jonas Johnson; Rob M van Dam
Journal:  World J Surg       Date:  2010-01       Impact factor: 3.352

5.  Pulmonary thromboembolism in lung surgery: use of unfractionated heparin.

Authors:  Junichi Yoshida; Masaaki Inoue; Koichi Furugaki; Mayumi Oyama; Keigo Oozono
Journal:  Asian Cardiovasc Thorac Ann       Date:  2013-10-22

6.  Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy.

Authors:  P D Stein; J W Henry
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

7.  Thromboembolism in patients undergoing thoracotomy.

Authors:  S Ziomek; R C Read; H G Tobler; J E Harrell; J C Gocio; L M Fink; T J Ranval; E J Ferris; D L Harshfield; D R McFarland
Journal:  Ann Thorac Surg       Date:  1993-08       Impact factor: 4.330

8.  Intermittent pneumatic compression is effective in preventing symptomatic pulmonary embolism after thoracic surgery.

Authors:  Itaru Nagahiro; Akio Andou; Motoi Aoe; Yoshifumi Sano; Hiroshi Date; Nobuyoshi Shimizu
Journal:  Surg Today       Date:  2004       Impact factor: 2.549

9.  Postoperative venous thromboembolism in Asia: a critical appraisal of its incidence.

Authors:  Ngoh Chin Liew; Kevin Moissinac; Yunus Gul
Journal:  Asian J Surg       Date:  2003-07       Impact factor: 2.767

10.  Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC).

Authors:  Adam Torbicki; Arnaud Perrier; Stavros Konstantinides; Giancarlo Agnelli; Nazzareno Galiè; Piotr Pruszczyk; Frank Bengel; Adrian J B Brady; Daniel Ferreira; Uwe Janssens; Walter Klepetko; Eckhard Mayer; Martine Remy-Jardin; Jean-Pierre Bassand
Journal:  Eur Heart J       Date:  2008-08-30       Impact factor: 29.983

View more
  3 in total

Review 1.  Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism.

Authors:  Stavros Kakkos; George Kirkilesis; Joseph A Caprini; George Geroulakos; Andrew Nicolaides; Gerard Stansby; Daniel J Reddy
Journal:  Cochrane Database Syst Rev       Date:  2022-01-28

Review 2.  Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation.

Authors:  Lara A Kahale; Charbel F Matar; Ibrahim Tsolakian; Maram B Hakoum; Maddalena Barba; Victor Ed Yosuico; Irene Terrenato; Francesca Sperati; Holger Schünemann; Elie A Akl
Journal:  Cochrane Database Syst Rev       Date:  2021-10-08

3.  American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.

Authors:  Gary H Lyman; Marc Carrier; Cihan Ay; Marcello Di Nisio; Lisa K Hicks; Alok A Khorana; Andrew D Leavitt; Agnes Y Y Lee; Fergus Macbeth; Rebecca L Morgan; Simon Noble; Elizabeth A Sexton; David Stenehjem; Wojtek Wiercioch; Lara A Kahale; Pablo Alonso-Coello
Journal:  Blood Adv       Date:  2021-02-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.